 Clinical Trials as Topic
"Clinical Trials as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
| Descriptor ID |
D002986
|
| MeSH Number(s) |
E05.318.760.535 E05.337.250 N05.715.360.775.235 N06.850.520.450.535
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials as Topic".
This graph shows the total number of publications written about "Clinical Trials as Topic" by people in this website by year, and whether "Clinical Trials as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 6 | 6 | | 1981 | 1 | 4 | 5 | | 1982 | 0 | 9 | 9 | | 1983 | 0 | 9 | 9 | | 1984 | 0 | 8 | 8 | | 1985 | 0 | 11 | 11 | | 1986 | 1 | 8 | 9 | | 1987 | 0 | 15 | 15 | | 1988 | 0 | 14 | 14 | | 1989 | 0 | 10 | 10 | | 1990 | 0 | 6 | 6 | | 1991 | 0 | 2 | 2 | | 1992 | 4 | 4 | 8 | | 1993 | 1 | 2 | 3 | | 1994 | 2 | 4 | 6 | | 1995 | 4 | 10 | 14 | | 1996 | 3 | 9 | 12 | | 1997 | 1 | 13 | 14 | | 1998 | 0 | 7 | 7 | | 1999 | 4 | 8 | 12 | | 2000 | 4 | 21 | 25 | | 2001 | 6 | 14 | 20 | | 2002 | 5 | 24 | 29 | | 2003 | 8 | 22 | 30 | | 2004 | 10 | 45 | 55 | | 2005 | 5 | 34 | 39 | | 2006 | 13 | 45 | 58 | | 2007 | 7 | 31 | 38 | | 2008 | 9 | 37 | 46 | | 2009 | 12 | 42 | 54 | | 2010 | 10 | 34 | 44 | | 2011 | 17 | 29 | 46 | | 2012 | 17 | 30 | 47 | | 2013 | 14 | 24 | 38 | | 2014 | 10 | 23 | 33 | | 2015 | 13 | 28 | 41 | | 2016 | 11 | 26 | 37 | | 2017 | 14 | 15 | 29 | | 2018 | 7 | 31 | 38 | | 2019 | 13 | 13 | 26 | | 2020 | 7 | 20 | 27 | | 2021 | 2 | 4 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials as Topic" by people in Profiles.
-
Krishnan ML, Berry-Kravis E, Capal JK, Carpenter R, Gringras P, Hipp JF, Miller MT, Mingorance A, Philpot BD, Pletcher MT, Rotenberg A, Tjeertes J, Wang PP, Willgoss T, de Wit MC, Jeste SS. Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities. Nat Rev Drug Discov. 2021 09; 20(9):653-654.
-
Sulmasy DP. Are SARS-CoV-2 Human Challenge Trials Ethical? JAMA Intern Med. 2021 08 01; 181(8):1031-1032.
-
Prischl FC, Rossing P, Bakris G, Mayer G, Wanner C. Major adverse renal events (MARE): a proposal to unify renal endpoints. Nephrol Dial Transplant. 2021 02 20; 36(3):491-497.
-
Kurbegov D, Hurley P, Waterhouse DM, Robert NJ, Nowakowski GS, Thompson MA, Bruinooge SS, Schilsky RL, Byatt L, Dempsey K, Dawson C, Hofacker J, Liu J, MacDougall AK, Kim ES. Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. JCO Oncol Pract. 2021 01; 17(1):41-51.
-
Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021 01 06; 14(1):7.
-
Vinson AJ, Chong AS, Clegg D, Falk C, Foster BJ, Halpin A, Mannon RB, Palmer BF, Oertelt-Prigione S, West LJ, Wong G, Sapir-Pichhadze R. Sex matters: COVID-19 in kidney transplantation. Kidney Int. 2021 03; 99(3):555-558.
-
Aggarwal R, Lu K, Chiu N, Bakris GL, Bhatt DL. U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. J Am Coll Cardiol. 2020 12 15; 76(24):2907-2910.
-
Pennell NA, Dillmon M, Levit LA, Moushey EA, Alva AS, Blau S, Cannon TL, Dickson NR, Diehn M, Gonen M, Gonzalez MM, Hensold JO, Hinyard LJ, King T, Lindsey SC, Magnuson A, Marron J, McAneny BL, McDonnell TM, Mileham KF, Nasso SF, Nowakowski GS, Oettel KR, Patel MI, Patt DA, Perlmutter J, Pickard TA, Rodriguez G, Rosenberg AR, Russo B, Szczepanek C, Smith CB, Srivastava P, Teplinsky E, Thota R, Traina TA, Zon R, Bourbeau B, Bruinooge SS, Foster S, Grubbs S, Hagerty K, Hurley P, Kamin D, Phillips J, Schenkel C, Schilsky RL, Burris HA. American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. J Clin Oncol. 2021 01 10; 39(2):155-169.
-
Patel AA, Odenike O. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418.
-
Prescott K, Jacobs M, Stock W, Wynne J. New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr Hematol Malig Rep. 2020 12; 15(6):424-435.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|